Product Description
Levobetaxolol is a cardioselective beta-blocker that has been demonstrated to reduce intraocular pressure in patients affected with primary open-angle glaucoma and ocular hypertension. Levobetaxolol may be an effective neuroprotectant because of its great capacity to block sodium and calcium influx, which might confer a neuroprotective activity (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704505/)
Mechanisms of Action: ADRB1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Approved
Approved Countries: India | Pakistan
Approved Indications: None
Known Adverse Events: None
Company: Alcon
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Hypertension|Glaucoma|Glaucoma, Open-Angle
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ZK-LBL-2016-01 | P3 |
Completed |
Glaucoma, Open-Angle|Hypertension |
2021-07-01 |
95% |
| C-00-17 | P3 |
Completed |
Hypertension|Glaucoma |
2006-02-01 |
|
| CTR20150505 | N/A |
Suspended |
Glaucoma |
None |
|
| CTR20170010 | N/A |
Suspended |
Hypertension|Glaucoma, Open-Angle |
None |